Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva ...

Meanwhile, sales of the products introduced to replace Advair/Seretide missed consensus estimates, with Breo (fluticasone furoate and vilanterol) bringing in £11 million and Anoro (umeclidinium ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...

“..Looking at Anoro’s paintings, we shouldn’t be surprised to learn that the artist describes his youth as a “Technicolor movie,” flush with colors and ...

The root of the U.S.’s high prescription drug prices lies in its unique system, which allows pharmaceutical manufacturers to ...